Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double‐blind randomized controlled trial
Journal of Gastroenterology and Hepatology · 2023
DOI: 10.1111/jgh.16266 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2023. Verfasst von Barjesh Chander Sharma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India. Hauptthemen laut MEDLINE: Cognitive Dysfunction, Hepatic Encephalopathy. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 45 Literaturangaben.
Abstract (Originalsprache)
Background and Aim Minimal hepatic encephalopathy (MHE) reflects cognitive impairment in patients with liver cirrhosis and is associated with poor prognosis. We assessed the effects of nutritional therapy on cognitive functions, health‐related quality of life (HRQOL), anthropometry, endotoxins, and inflammatory markers in cirrhotic patients with MHE.
Methods
In a double‐blind randomized controlled trial, cirrhotic patients with MHE were randomized to nutritional therapy (group I: 30–35 kcal/kg/day and 1.0–1.5 g of protein/kg/day) and no nutritional therapy (group II: diet as patients were taking before) for 6 months. MHE was diagnosed based on psychometric hepatic encephalopathy score (PHES). Anthropometry, ammonia, endotoxins, inflammatory markers, myostatin, and HRQOL were assessed at baseline and after 6 months. Primary endpoints were improvement or worsening in MHE and HRQOL.
Results
A total of 150 patients were randomized to group I ( n = 75, age 46.3 ± 12.5 years, 58 men) and group II ( n = 75, age 45.2 ± 9.3 years, 56 men). Baseline PHES (−8.16 ± 1.42 vs −8.24 ± 1.43; P = 0.54) was comparable in both groups. Reversal of MHE was higher in group I (73.2% vs 21.4%; P = 0.001) than group II. Improvement in PHES (Δ PHES 4.0 ± 0.60 vs −4.18 ± 0.40; P = 0.001), HRQOL (Δ Sickness Impact Profile 3.24 ± 3.63 vs 0.54 ± 3.58; P = 0.001), anthropometry, ammonia, endotoxins, cytokines, and myostatin levels was also significantly higher in group I than group II. Overt hepatic encephalopathy developed in 6 patients in group I and 13 in group II ( P = 0.04).
Conclusions
Nutritional therapy is effective in treatment of MHE and associated with improvement in nutritional status, HRQOL, ammonia, endotoxins, inflammatory markers, and myostatin levels.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
- Department of Gastroenterology, SMS Hospital, Jaipur, India.
- Department of Biochemistry, G.B. Pant Hospital, New Delhi, India.
- Department of Radiology, G.B. Pant Hospital, New Delhi, India.
ORCID-Profile: Barjesh Chander Sharma, Sudhir Maharshi, Siddharth Srivastava, Ajay Kumar, Ashok Dalal, Ujjwal Sonika
Zitieren
APA
Sharma, B. C., Maharshi, S., Sachdeva, S., Mahajan, B., Sharma, A., Bara, S., Srivastava, S., Kumar, A., Dalal, A., & Sonika, U. (2023). Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double‐blind randomized controlled trial. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16266
Vancouver
Sharma BC, Maharshi S, Sachdeva S, Mahajan B, Sharma A, Bara S, et al. Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double‐blind randomized controlled trial. Journal of Gastroenterology and Hepatology. 2023. doi:10.1111/jgh.16266
BibTeX
@article{Sharma2023,
author = {Sharma, Barjesh Chander and Maharshi, Sudhir and Sachdeva, Sanjeev and Mahajan, Bhawna and Sharma, Ashok and Bara, Sushma and Srivastava, Siddharth and Kumar, Ajay and Dalal, Ashok and Sonika, Ujjwal},
title = {Nutritional therapy for persistent cognitive impairment after resolution of overt hepatic encephalopathy in patients with cirrhosis: A double‐blind randomized controlled trial},
journal = {Journal of Gastroenterology and Hepatology},
year = {2023},
doi = {10.1111/jgh.16266}
}
EUVIMED